ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma's Innovative Injectable Aesthetics Portfolio and Pipeline
At ASDS 2025, Galderma unveiled pivotal new data from its range of pioneering Restylane® hyaluronic acid (HA) injectables, highlighting its versatility in improving the chin profile with Restylane Lyft™, temple volume with investigational Restylane Contour™*
(Financial Post, 2025-11-17T06:04:50Z)